Abstract
We studied the safety, activity and peripheral blood progenitor cell mobilizing capability of a dose-dense combination of vinorelbine (VNB) and paclitaxel (PTX) as first-line chemotherapy for patients with metastatic breast cancer (MBC). Forty-three MBC patients were submitted to four cycles of VNB 30 mg/m2 and PTX 175 mg/m2 intravenously, every 2 weeks, as the first induction step of a tandem high-dose chemotherapy program. Granulocyte colony-stimulating factor (G-CSF) 5 µg/kg was administered daily from day +5 to +10 in order to accelerate hematopoietic recovery, or 48 h after the last VNB–PTX when a leukapheresis was planned (after the third or fourth cycle). A total of 172 cycles were administered. The mean delivered dose-intensity of VNB and PTX was 14.7 and 86 mg/m2/week, respectively (98% of the planned dose-intensity). The main per-patient toxicities were: peripheral neurotoxicity (G1/2 60%, G3 5%), constipation (G1/2 10%), oral mucositis (G1/2 20%), and asthenia (G1/2 35%). Hematological toxicity was unremarkable, except for anemia with hemoglobin (Hb) values <10 g/dl (28%), and lymphopenia with lymphocyte counts <1000/mm3 (28%). Two complete (5.1%) and 24 partial (61.5%) responses were observed in 39 assessable patients, for an overall response rate of 66.6% (95% CI 51.6–80.9). A median of one apheretic procedure (range 1–3) was required to achieve the target number of 6 × 106/kg CD34+ cells. The median number of CD34+ harvested per patient was 15 × 106/kg (range 6.4–36.5). Four cycles of dose dense VNB and PTX showed a favorable toxicity profile, a relevant anti-tumor activity and a high peripheral blood progenitor cell mobilizing activity.
Similar content being viewed by others
References
Vogel CL, Nabholtz JM: Monotherapy of metastatic breast cancer: a review of newer agents. Oncologist 4: 17-33, 1999
Knick VC, Eberwein DJ, Miller CG: Vinorelbine tartrate and paclitaxel combinations: enhanced activity against in vivo P388 murine leukemia cells. J Natl Cancer Inst 87: 1072-1077, 1995
Kano Y, Akutsu M, Suzuki K, Ando J, Tsunoda S: Schedule-dependent interactions between vinorelbine and paclitaxel in human carcinoma cell lines in vitro. Breast Cancer Res Treat 56: 79-90, 1999
Livingston RB, Ellis GK, Gralow JR, Williams MA, White R, McGuirt C, Adamkiewicz BB, Long CA: Dose-intensive vinorelbine with concurrent granulocyte colony-stimulating factor support in paclitaxel-refractory metastatic breast cancer. J Clin Oncol 15: 1395-1400, 1997
Ellis GK, Gralow JR, Pierce HI, Williams MA, Livingston RB: Infusional paclitaxel and weekly vinorelbine chemotherapy with concurrent filgrastim for metastatic breast cancer: high complete response rate in a phase I-II study of doxorubicintreated patients. J Clin Oncol 17: 1407-1412, 1999
Romero AL, Langhi M, Perez J, Romero AJ, Machiavelli M, Lacava J, Vallejo C, Romero A, Fasce H, Ortiz E, Grasso S, Amato S, Rodriguez R, Barbieri M, Leone B: Vinorelbine and paclitaxel as first-line chemotherapy in metastatic breast cancer. J Clin Oncol 17: 74-81, 1999
Vici P, Amodio A, Di Lauro L, Conti F, Gionfra T, Belli F, Lopez M: First-line chemotherapy with vinorelbine and paclitaxel as simultaneous infusion in advanced breast cancer. Oncology 58: 3-7, 2000
Martin M, Lluch A, Casado A, Garciia CI, de Paz L, Esteban C, Insa A, Alfonso R, Garcia-Conde J, Diaz-Rubio E: Paclitaxel plus vinorelbine: an active regimen in metastatic breast cancer patients with prior anthracycline exposure. Ann Oncol 11: 85-89, 2000
Ibrahim NK, Buzdar AU, Valero V, Dhingra K, Willey J, Hortobagyi GN: Phase I study of vinorelbine and paclitaxel by 3-hour simultaneous infusion with and without granulocyte colony-stimulating factor support in metastatic breast carcinoma. Cancer 91: 664-671, 2001
Esteva FJ, Valero V, Pusztai L, Boehnke-Michaud L, Buzdar AU, Hortobagyi GN: Chemotherapy of metastatic breast cancer: what to expect in 2001 and beyond. Oncologist 6: 133-146, 2001
Fossati R, Confalonieri C, Torri V, Ghislandi E, Penna A, Pistotti V, Tinazzi A, Liberati A: Cytotoxic and hormonal treatment for metastatic breast cancer: a systematic review of published randomized trials involving 31,510 women. J Clin Oncol 16: 3439-3460, 1998
Norton L: Evolving concepts in the systemic drug therapy of breast cancer. Semin Oncol 24: S10-S10, 1997
World Health Organization: Handbook for Reporting Results of Cancer Treatment. WHO, Geneva, 1979
Miller AB, Hoogstraten B, Staquet M, Winkler A: Reporting results of cancer treatment. Cancer 47: 207-214, 1981
Siena S, Bregni M, Brando B, Belli N, Ravagnani F, Gandola L, Stern AC, Lansdorp PM, Bonadonna G, Gianni AM: Flow cytometry for clinical estimation of circulating hematopoietic progenitors for autologous transplantation in cancer patients. Blood 77: 400-409, 1991
Miettinen OS: Estimation of relative risk from individually matched series. Biometrics 26: 75-86, 1970
Biganzoli L, Cufer T, Bruning P, Coleman R, Duchateau L, Calvert AH, Gamucci T, Twelves C, Fargeot P, Epelbaum R, Lohrisch C, Piccart MJ: Doxorubicin and paclitaxel versus doxorubicin and cyclophosphamide as first-line chemotherapy in metastatic breast cancer: The European Organization for Research and Treatment of Cancer 10961 Multicenter Phase III Trial. J Clin Oncol 20: 3114-3121, 2002
Demirer T, Rowley S, Buckner CD, Appelbaum FR, Lilleby K, Storb R, Schiffman K, Bensinger WI: Peripheral-blood stem-cell collections after paclitaxel, cyclophosphamide, and recombinant human granulocyte colony-stimulating factor in patients with breast and ovarian cancer. J Clin Oncol 13: 1714-1719, 1995
Pedrazzoli P, Perotti C, Da Prada GA, Bertolini F, Gibelli N, Torretta L, Battaglia M, Pavesi L, Preti P, Salvaneschi L, Robustelli della CG: Collection of circulating progenitor cells after epirubicin, paclitaxel and filgrastim in patients with metastatic breast cancer. Br J Cancer 75: 1368-1372, 1997
Baynes RD, Dansey RD, Klein JL, Karanes C, Cassells L, Abella E, Wei WZ, Galy A, Du W, Wood G, Peters WP: High-dose chemotherapy and autologous stem cell transplantation for breast cancer. Cancer Invest 18: 440-455, 2000
Berry DA, Broadwater G, Klein JP, Antman K, Aisner J, Bitran J, Costanza M, Freytes CO, Stadtmauer E, Gale RP, Henderson IC, Lazarus HM, McCarthy Jr. PL, Norton L, Parnes H, Pecora A, Perry MC, Rowlings P, Spitzer G, Horowitz MM: High-dose versus standard chemotherapy in metastatic breast cancer: comparison of Cancer and Leukemia Group B Trials with data from the Autologous Blood and Marrow Transplant Registry. J Clin Oncol 20: 743-750, 2002
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Ballestrero, A., Montemurro, F., Gonella, R. et al. Dose-dense Vinorelbine and Paclitaxel with Granulocyte Colony-stimulating Factor in Metastatic Breast Cancer Patients: Anti-tumor Activity and Peripheral Blood Progenitor Cell Mobilization Capability. Breast Cancer Res Treat 82, 185–190 (2003). https://doi.org/10.1023/B:BREA.0000004374.72658.17
Issue Date:
DOI: https://doi.org/10.1023/B:BREA.0000004374.72658.17